issued shares in Indo Rama Synthetics (India) Limited (“IRSL”), equaling to approximately 31.79% of IRSL’s enlarged share capital (the “Share Purchase”) at the price of INR 36 per share. The Company would
by its indirect subsidiary Indorama Netherlands B.V. (“INBV”) of 83,000,000 newly issued shares in Indo Rama Synthetics (India) Limited (“IRSL”), equaling to approximately 31.79% of IRSL’s enlarged
or 22.90% over the same period of last year of which hospital revenues totally raised by 10.16% along with the enlarged customer base of Subsidiary (AMARC) showing 15.67% of revenues’ growth. In
increased ,while the Social security revenue of subsidiaries decreased. Payment system of Social security office is uncertain therefore in Q1/2019 subsidiaries did not receive revenue of chromic disease. 2
year, the Company has not yet earned income from Excellence Center (New Building) planned to official grand opening in the following year of February 2018) along with the enlarged customer base of the
premium at no more than 90 million baht is not appropriate since 150-200 MW power plant project and the associated consignments remain uncertain while additional investment of 7,850 million baht is needed
shareholders, and subscribe Phoenix’s newly issued shares of 180.00 million shares, totaling 314.60 million shares or 55 percent of total enlarged shares of Phoenix. List of shareholders before and after
performance in 2nd quarter and 6-month period, its cost of services amounted to Baht 21.3 million and Baht 45.4 million, a rise of 12.4% and 20.5% whereas its selling & administrative expenses enlarged at
and the PPA remain unclear and uncertain while additional investment of 7,850 million baht is needed, causing IFA unable to appraise the project value; (3) various risks associated with the transaction